The UK Medicines and Healthcare products Regulatory Agency (MHRA) announced on 9 November 2026 that three investigational medicines have been granted Innovation Passports under the Innovative Licensing and Access Pathway (ILAP). The awards cover a small interfering RNA therapy for Huntington's disease, a small molecule oncology therapy with first-line non-small cell lung cancer (NSCLC) expected as its lead indication, and an antisense oligonucleotide for early Alzheimer's disease.

The MHRA describes ILAP as a route allowing developers to work from early clinical development with the national health system, the regulator and health technology assessment bodies. The agency said the pathway is intended to reduce development risk and speed patient access to new medicines. It noted that the treatments remain in development and that future availability will depend on evidence of safety, effectiveness and value. The source also states that applications for the next round of Innovation Passports opened on 9 November and remain open until 11 February 2027.

The announcement cited disease burden figures, including that NSCLC accounts for around 80–85% of lung cancer cases, that around 50,200 people are diagnosed with lung cancer in the UK each year, and that an estimated 982,000 people were living with dementia in the UK in 2024. Partners including NICE, the Scottish Medicines Consortium and the All Wales Therapeutics and Toxicology Centre welcomed the designations, while company representatives for the three therapies commented on their development plans.